Drug Trial Radar · NCT03090100
A Study to Evaluate the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis
Last checked: Nov 20, 2026Latest source record: Oct 1, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,048
Actual
Start
Apr 27, 2017
Primary completion
Aug 2, 2018
Study completion Sep 20, 2018
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Mar 24, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy of guselkumab compared with secukinumab for the treatment of participants with moderate to severe plaque-type psoriasis.
Conditions
- Psoriasis
Interventions
GuselkumabDrug
Participants will receive 1 injection of active guselkumab at Weeks 0, 4, 12, 20, 28, 36, and 44.
PlaceboDrug
Participants will receive 1 injection of placebo at Weeks 0, 4, 12, 20, 28, 36, and 44 and 2 injections of placebo at Weeks 1, 2, 3, 8, 16, 24, 32, and 40.
SecukinumabDrug
Participants will receive 2 injections of active secukinumab at Weeks 0, 1, 2, 3, 4 and every 4 weeks (q4w) thereafter through Week 44.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Who Achieved a Psoriasis Area and Severity Index (PASI)-90 Response at Week 48Time frame: Week 48
Locations
142 sites in 9 countries. Site status is shown where the registry gives one.
University of Alabama Birmingham
Birmingham, Alabama
Southern California Permanente Medical Group
Los Angeles, California
Dermatology Specialists
Oceanside, California
MedDerm Associates
San Diego, California
San Luis Dermatology & Laser Clinic, Inc
San Luis Obispo, California
Southern California Dermatology
Santa Ana, California
Clinical Research Center of Connecticut
Danbury, Connecticut
Olympian Clinical Research
Clearwater, Florida
Florida Academic Dermatology Centers
Coral Gables, Florida
Renstar Medical Research
Ocala, Florida
Park Avenue Dermatology
Orange Park, Florida
Atlanta Dermatology, Vein & Research Center
Alpharetta, Georgia
Advanced Medical Research
Atlanta, Georgia
Marietta Dermatology Clinical Research
Marietta, Georgia
Arlington Dermatology
Rolling Meadows, Illinois
Northshore Universite Healthsystem
Skokie, Illinois
Dawes Fretzin Clinical Research Group
Indianapolis, Indiana
Indiana Clinical Trial Center
Plainfield, Indiana
Dermatology Specialists
Louisville, Kentucky
DermAssociates, PC
Rockville, Maryland
Great Lakes Research Group
Bay City, Michigan
Henry Ford Medical Center
Detroit, Michigan
Hamzavi Dermatology
Fort Gratiot, Michigan
Somerset Skin Centre
Troy, Michigan
Minnesota Clinical Study Center
Fridley, Minnesota
Central Dermatology
St Louis, Missouri
Windsor Dermatology
East Windsor, New Jersey
Academic Dermatology Associates
Albuquerque, New Mexico
Dermatology Consulting Services, PLLC
High Point, North Carolina
Dermatologists of Greater Columbus
Bexley, Ohio
The Ohio State University
Gahanna, Ohio
Central Sooner Research
Norman, Oklahoma
Oregon Dermatology and Research Center
Portland, Oregon
Oregon Medical Research Center
Portland, Oregon
University of Pittsburgh Department of Dermatology
Pittsburgh, Pennsylvania
Clinical Partners
Johnston, Rhode Island
Austin Dermatology Associates
Austin, Texas
Modern Research Associates
Dallas, Texas
Menter Dermatology Research Institute
Dallas, Texas
Suzanne Bruce and Associates - The Center for Skin Research
Houston, Texas
Showing 40 of 142 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.